W Yong1, Y Zhang, W Zheng. 1. Beijing Medical University, School of Oncology, Beijing Cancer Hospital, Beijing 100036, China.
Abstract
OBJECTIVE: To improve the treatment outcome of refractory midline peripheral T-cell lymphoma (MPTCL). METHOD: Eleven patients with refractory MPTCL received salvage chemotherapy consisting of L-asparaginase(L-ASP), vincristine and dexamethosone (L-ASP group), and 10 patients received combined chemotherapy without L-ASP(control group). The response rates and 2 year survival rates were observed. RESULTS: Response rates were 63.6% for L-ASP group and 10.0% for control group (P < 0.05), and 2 year survival rates were 45.5% and 0 (P < 0.05), respectively. The major side effects of L-ASP were leukocytopenia, elevation of serum bilirubin and hyperglycemia. CONCLUSION: The L-ASP-based salvage chemotherapy improved the response rate and 2 year survival rate of the patients with refractory MPTCL.
OBJECTIVE: To improve the treatment outcome of refractory midline peripheral T-cell lymphoma (MPTCL). METHOD: Eleven patients with refractory MPTCL received salvage chemotherapy consisting of L-asparaginase(L-ASP), vincristine and dexamethosone (L-ASP group), and 10 patients received combined chemotherapy without L-ASP(control group). The response rates and 2 year survival rates were observed. RESULTS: Response rates were 63.6% for L-ASP group and 10.0% for control group (P < 0.05), and 2 year survival rates were 45.5% and 0 (P < 0.05), respectively. The major side effects of L-ASP were leukocytopenia, elevation of serum bilirubin and hyperglycemia. CONCLUSION: The L-ASP-based salvage chemotherapy improved the response rate and 2 year survival rate of the patients with refractory MPTCL.